The objective was to determine how miRNA expression levels related to obesity and weight loss interacted, to forecast how much weight patients could lose after surgery, and to maximize the advantages of a scheduled procedure. 17 patients who planned laparoscopic sleeve gastrectomy were included. Demographic variables, comorbid conditions, and postoperative excess weight loss rates (EWL%) were evaluated. Both intraoperative adipose tissue samples and blood samples were taken. The gene expression levels of the miRNAs (miR27b-3p, miR122- 5p, and miR223-3p) linked to diabetes and obesity were investigated. Mean body mass index was 49.17.6 kg/m2. Six individuals had diabetes mellitus, and their mean blood sugar and HbA1c levels were 133±59.4 mg/dl and 6.4±1.3%, respectively. All preoperative groups had considerably higher levels of miR223-3p expression, it was discovered. Blood samples taken before and after surgery showed considerably higher levels of miR223-3p gene expression than those of miR27b-3p and miR122-5p. Additionally, it was discovered that in individuals with diabetes mellitus, miR122-5p gene expression in fatty tissue was lower than that of miR223-3p and miR27b-3p. MiR223-3p expression has been linked to morbidly obese patients, particularly those with EWLs of 50% and above. After bariatric surgery, the miR223-3p gene may be utilized as a potential biomarker to predict a patient's capacity to lose weight. It is possible to identify patients who will not benefit from surgery and decide to perform a different kind of operation on them. However, additional research involving more patients, additional miRNAs, and various bariatric surgery techniques is required.
Key words: Obesity,miR223-3p,biomarker,bariatric surgery
|
